Matt Cooper

🙌…and therapy developers push even harder to implement our revolutionary Celledonia™️ cell analyser at scale. 🏴󠁧󠁢󠁳󠁣󠁴󠁿An homage to Caledonia squared to the power of Celidonius (“a man born blind whom Jesus healed in the Gospel of John 9:1–38”): AuraCyt empowers our industry to finally “See the Unseen”… 1️⃣ predicting the unpredictable: high-producing clones in Cell Line Development - saving 3-6 crucial months in that process, every single time; 🧫 2️⃣ enabling scale-out of CGT to manufacture the unmanufacturable; 🧬 3️⃣ unlocking automation with rapid cell analysis for direct CGT process control;⏰ https://lnkd.in/e_bPw6Wz https://lnkd.in/eUE2Fhdw #CellAnalysis game-changer 👾| #CellAndGene | #CGT 🧬| #AdvancedTherapies 🧪 #SpeedToMarket 🏁 | #SpeedToPatient 👩‍🔬⌛️👨‍🔬

22

I am incredibly proud to announce that we have been awarded a £1.6M project from Innovate UK’s Biomedical Catalyst 2023 Round 2: Industry-led R&D 🙌 This application took a tremendous amount of effort, including working well into the early hours of many mornings to perfect the initial submission and cancelling leave over Christmas to prepare for the interview stage. Innovate UK grants (rightly!) require significant work; the application is scrutinised by five experienced assessors from various areas across Life Sciences. The next-stage interview is then attended by up to ten other people, with our panel including professionals from the NHS, academia, and CDMOs, among others. With a pot of £17.8M, and average project cost at £415,191, only 30 of the 358 applications could be funded 💰 . It is therefore truly gratifying to have so many experts agree that the cause we are developing solutions for is important and worthy of this substantial investment ✊ We do not take this funding lightly and will work tirelessly to ensure the success of our exciting project. Time to get cracking! https://lnkd.in/ev58aTt8 #biomedicalcatalyst #healthcare #infantmicrobiome #microbiome #grantfunding #grants #investment #innovateuk #biotech

463

54 Comments

Congratulations Purespring Therapeutics 🎉 Recently they announced raising £80m in an oversubscribed Series B financing round. This funding will be used to accelerate the development of their novel podocyte-targeting AAV #GeneTherapy platform, which has the potential to transform the lives of the 840 million people globally with kidney diseases. This includes advancing their lead programme, PS-002, which targets IgA Nephropathy (IgAN), a common, chronic kidney disease affecting young adults, towards a Phase I/II #ClinicalTrial. There are currently no therapeutic options to stop disease progression, nor a cure, and nearly one third of IgAN patients will go on to lose their kidney function within five years and require a kidney transplant or dialysis. #genetherapy #kidneydisease https://lnkd.in/gjBZbDkD

1

Are you a manufacturer of Digital Therapeutics (DTx) with a focus on the UK market? In this blog post, we delve into the intricacies of Digital Therapeutics (DTx) regulation in the UK, especially in light of Brexit in January 2020. 👉 https://lnkd.in/eqYb38ZF #DTx #DigitalTherapeutics #RegulatoryAffairs #Brexit

11

How do growth factors produce cell division? Growth factors promote cell proliferation by initiating a chain of events when they bind to their receptors, which ripple through the cell. Our latest blog article explains these events. https://lnkd.in/eSS-qsjS

17

Rapid, detailed cell analysis technology soon ready to assess the difference it can make to process insights and timelines

11

https://lnkd.in/eMnPdwZs Read the latest blog on the comparison of molecular detection Techniques: SYBR Green Vs. TaqMan written by our expert Product Manager John Probert at 2BScientific Ltd. #TaqMan and #SYBR Green #PCR techniques are critical for research in molecular biology, driving advancements in investigations and diagnostics. Here’s why they're essential: Gene Expression Analysis and Biomarker Detection: SYBR Green PCR for screening, followed by TaqMan PCR for precise quantification and validation. Microbial Detection and Oncology: SYBR Green PCR for broad screening, TaqMan PCR for accurate quantification of specific targets. Epigenetics Studies, Pharmacogenomics, and Personalised Medicine: SYBR Green PCR's early assessment complements TaqMan PCR's precision, aiding informed treatment decisions. Check out the detailed article from 2BScientific covering the utilisation of TaqMan and SYBR Green, along with our selection of superior research reagents suitable for PCR and various research applications. #hereforyou #2bscientific #molecular

7

This is such an important subject and a big thanks to British In Vitro Diagnostics Association (BIVDA) for raising it at a Parliamentary Reception this week. Getting innovations into the NHS is challenging, especially for SMEs who have limited resources and significant pressures from their investors to get sales. One of the unfortunate consequences of this is that SMEs are forced to focus their efforts on larger international markets with quicker pathways to adoption, and UK patients cannot access homegrown innovations. Surely there must be a way to reduce the barriers to adoption to ensure British innovations are available in their home market first? #skincancer #melanoma #diagnostic # innovation #AMBLor

24

1 Comment

In the Department for Science, Innovation and Technology first #lifesciences related announcement, the UK Biobank, the world’s leading biomedical database, has been given a major boost. Amazon Web Services (AWS) will provide £8 million worth of cloud computing storage access, unlocking an additional £8 million in match-funding from the #ukgovernment. This combined £16 million investment will support vital research aimed at developing new #diagnostics and treatments for diseases such as #Parkinson’s, #dementia, and #cancer. AWS's contribution will equip UK Biobank with the necessary cloud infrastructure to securely store and manage its extensive health #data. This initiative is part of a broader effort, which began with a public-philanthropic consortium formed last year, to secure UK Biobank’s future. With today’s announcement, nearly £50 million has been raised. UK Biobank’s unparalleled dataset, consisting of genetic, health, and lifestyle information from 500,000 UK volunteers, is a crucial resource for researchers worldwide. This support from AWS and the government ensures that UK Biobank remains at the forefront of medical research, driving #innovation which will transform healthcare and improve lives both domestically and globally.

8

Fantastic set of talks today highlighting the unsung hero of drug discovery - Enzymology. Sincere thanks to Argyrides Argyrou , Claire McWhirter and Karl Syson for organising such a valuable and engaging symposium, AstraZeneca for hosting and all the speakers for their fantastic presentations! Really important topics discussed including the non-equilibrium environment of biological systems and the requirement for drug and target to be bound in order to have an effect, and the risks of using oversimplified metrics to support programme progression (from simply underestimating affinity through to fundamentally flawed selections). Data is of critical importance to effectively power decision-making and context is key. With the evolving ecosystem of instrumentation (including BMG LABTECH, SPT Labtech, FORMULATRIX, Tecan) reagents (including Cisbio, Revvity, Promega UK) and analytical capabilities (Genedata, GraphPad Prism) all now delivering the quality and consistency required to deliver the data resolution required, these concepts are becoming more readily accessible. Reflecting on the morning session over lunch highlights to me the still largely untapped potential of kinetic information. As an industry, we have been here before, discussing the advances in capabilities and significant merits on offer. However, this has largely been to an audience that is already receptive and uptake has remained pretty flat. So, how do we shift the dial? My personal view is that success is inextricably connected to more effective communication - I will expand on this concept in a future post. However, I’d love to hear your ideas on how you think we should tackle the challenges we face in translating untapped potential into tangible value. Please leave your thoughts below ⬇️ and follow/connect with me if you are keen to contribute to the discussion! #enzymology #kinetics #futuresuccess

84

6 Comments

Well, another affirmation that the Vodori content management solution is the only option for pharma, biotech or med tech companies regardless of size. If you want to review and approve interactive web content without relying on pdfs, call the Vodori folks. Another solid win for Vodori. Time to check it out yourself and ignore the sales folks from big tech. Congrats to the whole team #dumpveevabeforeitstoolate #freethemlrpeople #mlrcontentmanagement

15

3 Comments

Antimicrobial Resistance (AMR) is a serious threat to global public health. The UK government has recently announced a new action plan to combat AMR, which includes support for industries to develop new treatments. I believe that a similar action plan is needed in India. AMR is a major problem in India, and it is essential that we take steps to address it. The Indian government should provide support to industries for the development of new treatments and diagnostics for AMR. This could include financial incentives, such as tax breaks or grants, as well as regulatory support, such as fast-tracking the approval process for new drugs/diagnostics. Organisations like Biotechnology Industry Research Assistance Council (BIRAC) are already doing it, but more is needed. The government and industries should also work to raise awareness of AMR among the public and healthcare professionals. This could be done through public health campaigns and educational programs. #publichealth #amr #policy Module Innovations

11

SMALL CAP IDEA: Time to add Hemogenyx Pharma to the watchlist https://lnkd.in/e5xWgbha

19

On 24 April, Blue Matter convened a group of C-level executives from the UK #biotech industry to discuss a range of strategic topics. Here is a concise summary of the discussion & some key takeaways: https://lnkd.in/eQB9sEWd Authors: Damien Downes & Charlotte Culpin #pharmaceutical #biopharma #biotechnology

101

3 Comments

Are you a #biotech or #healthinnovation company looking to #raisefunds? Can you be in #London on 4th December 2024?? Are you interested in meeting a mixture of US and European Investors??? If you answer yes, please read on! RESI London 2024 is the most cost-effective opportunity you will get to attend such a high-quality, high-engagement and high-value event full of investors. What's more, it's in the UK, so for many of our #AgileLeaders network, not too far to travel! The folks at Life Science Nation are world-renowned for their #RESI investment conferences. This #RESILondon investor conference is in collaboration with One Nucleus's Genesis conference. The RESI London event merges with the #GenesisLondon 2024 at 4.30 pm on the 4 December for further networking. The venues are less than 5 minutes walk away from each other at the King's Fund on Cavendish Square and the Royal Medical Society at 1 Wimpole Street respectively. This event activity is terrific for #lifesciences in the #UK and we expect it to boost #earlystage investment for the #UK community. What's more, by using the code AgileLeaders15 you get 15% off these already great attendance rates!!! Qualified Investors go for free, so go to the RESI website to register for free if you're a qualified investor - no investment consultants or non-qualified non-professional investors need to apply. Stringent vetting is applied to all free investor applications. What RESI do exceptionally well is have qualified information on all their #investors attending so you can tell on the partnering system if they are potentially the right investor for you, or not. Typically these #RESI events have a 50:50 ratio of investors to #innovationcompanies, and this London event will be no exception. If you are a #drug, #device, #diagnostic or #digitalhealth #innovation company looking for #funding, this is a “must attend” event.  To register visit the RESI London website now to get this great 15% off deal using the AgileLeaders15 discount code. You won't get a better deal anywhere else. Space is limited, so I suggest you book your ticket ASAP to avoid any disappointment: https://lnkd.in/eSEnayPD Sponsorship Opportunities: If you are a service company, law firm or consultancy firm wanting to mix and be visible with these emerging innovation company CXOs and investors, there are some brilliant sponsorship options too, so get in touch if you are interested. For example there is an exhibitor and logo sponsorship package available for only £1,500 with two delegates, which I hope you agree is terrific value.

4

New report from London Economics - https://lnkd.in/eG6tmMaZ - highlights how the reduction in R&D tax relief for SMEs, coupled with increased relief for larger companies, risks stifling innovation in sectors where smaller firms play a crucial role. The report calls for a more nuanced, sector-specific approach to evaluating and implementing R&D tax relief which aligns with the need for fundamental changes to better support UK SMEs and foster genuine innovation across all sectors.

11

IRB Approval for Phase I Clinical Trial Hemogenyx Pharmaceuticals plc (LSE: HEMO), a biopharmaceutical company developing innovative therapies and treatments for blood diseases, is pleased to announce that the Institutional Review Board (IRB) of the Company's first clinical site has granted approval to initiate a Phase I clinical trial of the Company's lead asset, HEMO-CAR-T, which has now been given the formal designation HG-CT-1, for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults.   The proposed Phase 1 clinical trial is designed as a dose escalation study to assess the safety of HG-CT-1 in adult patients with R/R AML. Secondary clinical objectives are crucial for evaluating the broader impact of HG-CT-1 and include: ·      Estimating the efficacy of HG-CT-1 based on standard clinical response criteria for AML. ·      Estimating overall survival (OS) in evaluable subjects. ·      Estimating progression-free survival (PFS) in evaluable subjects. ·      Estimating duration of response (DoR) in evaluable subjects who achieve a clinical response.   These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options. This IRB approval represents a significant milestone for Hemogenyx Pharmaceuticals, enabling the Company to advance this promising therapy into clinical testing at one of the world's most prestigious cancer research institutions. https://lnkd.in/ewRsH4kz

29